非布司他在高尿酸血症合并未透析4-5期慢性肾脏病患者中的降尿酸疗效与肾脏安全性:观察性研究的Meta分析
通过Meta分析评估非布司他在未透析4-5期慢性肾脏病合并高尿酸血症患者中的降尿酸疗效与肾脏安全性。共纳入5项观察性研究、327例患者,非布司他每日10-120 mg、疗程3-12个月。血清尿酸加权均数差为-1.85 mg/dL(95%CI -2.04--1.67 mg/dL,I²=0%);eGFR加权均数差为0.11 mL/min/1.73m²(95%CI -0.25-0.47 mL/min/1.73m²,I²=45%)。结论认为非布司他具有可接受的降尿酸疗效与肾脏安全性。
要点
- 5项观察性研究、327例未透析4-5期CKD患者纳入分析。
- 非布司他降尿酸:加权均数差-1.85 mg/dL(95%CI -2.04--1.67,I²=0%)。
- eGFR变化:加权均数差0.11 mL/min/1.73m²(95%CI -0.25-0.47,I²=45%)。
核心结论
- 非布司他在高尿酸血症合并未透析4-5期慢性肾脏病患者中具有可接受的降尿酸疗效与肾脏安全性。
研究设计与样本
- PubMed、Ovid MEDLINE、Embase和Cochrane Library系统检索观察性研究。
- 最终纳入5项相关观察性研究,共327例患者。
- 非布司他每日给药剂量为10-120 mg,疗程为3-12个月。
主要发现
- 血清尿酸较基线下降,加权均数差为-1.85 mg/dL(95%CI -2.04--1.67 mg/dL,I²=0%)。
- 3项研究共145例患者纳入eGFR评估,eGFR在使用非布司他后无变化,加权均数差为0.11 mL/min/1.73m²(95%CI -0.25-0.47 mL/min/1.73m²,I²=45%)。
关键数值与推荐
- 血清尿酸变化:加权均数差-1.85 mg/dL(95%CI -2.04--1.67 mg/dL,I²=0%)。
- eGFR变化:加权均数差0.11 mL/min/1.73m²(95%CI -0.25-0.47 mL/min/1.73m²,I²=45%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- eGFR分析的异质性I²=45%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The efficacy and safety of febuxostat in patients with stage 4-5 chronic kidney disease (CKD) remains unclear. We evaluated the urate-lowering efficacy and renal safety of febuxostat in patients with stage 4-5 CKD not yet on dialysis, through a meta-analysis of observational studies. METHODS: We performed a systematic search in PubMed, Ovid MEDLINE, Embase, and the Cochrane Library databases for observational studies of patients with advanced CKD starting febuxostat. Articles describing changes in serum urate levels and/or renal function assessed by the estimated glomerular filtration rate (eGFR) were included. RESULTS: Among 148 retrieved studies, five relevant observational studies with 327 patients were included in the meta-analysis. Febuxostat was administered daily at 10-120 mg for 3-12 months. Serum urate reduced in response to febuxostat (weighted mean difference, -1.85 mg/dL; 95% CI, -2.04--1.67 mg/dL; I2; 0%). Three studies involving 145 patients included eGFR assessments. Renal function, assessed through the eGFR, did not change after febuxostat use (weighted mean difference, 0.11 mL/min/1.73m2; 95% CI, -0.25-0.47 mL/min/1.73m2; I2; 45%). CONCLUSION: Overall, febuxostat has acceptable urate-lowering efficacy and renal safety in patients with hyperuricemia and stage 4-5 CKD who are not yet on dialysis.
引用
- Jeong HJ, Park WY, Kim SH, et al. Urate-lowering efficacy and renal safety of febuxostat in patients with hyperuricemia and stage 4-5 chronic kidney disease not yet on dialysis: A meta-analysis of observational studies. Semin Arthritis Rheum. 2022. PMID: 35914389. doi:10.1016/j.semarthrit.2022.152073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。